The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of July 17, 2017.
Hi, I’m Kelly Davio for the Center for Biosimilars, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars. Here are our top 5 biosimilars articles for the week of July 17:
Number 5: A new report shows that most US-based health plans now cover at least 1 of the 2 available FDA-approved biosimilars.
Number 4: A phase 3 trial of the proposed rituximab biosimilar candidate GP2013 shows positive results in patients with follicular lymphoma.
Number 3: Molly Billstein Leber, manager of Medication Policy and Formulary Management for the Yale New Haven Health System, discusses the FDA’s Oncologic Drugs Advisory Committee’s unanimous recommendation of approval for biosimilars to Avastin and Herceptin.
Number 2: At this week’s public meeting on the Hatch-Waxman Amendments, FDA Commissioner Dr Scott Gottlieb announced the upcoming publication of 2 documents related to the ANDA process.
And finally, Number 1: The FDA Reauthorization Act may proceed to a Senate vote sooner rather than later after the failure of the Better Care Reconciliation Act.
Read these articles and more at centerforbiosimilars.com